Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa
Authored by Esther E Freeman, Richard G White, Roe Bakker, Kate K Orroth, Helen A Weiss, Anne Buve, Richard J Hayes, Judith R Glynn
Date Published: 2009
DOI: 10.1016/j.vaccine.2008.11.074
Sponsors:
Wellcome Trust
Platforms:
No platforms listed
Model Documentation:
Other Narrative
Model Code URLs:
Model code not found
Abstract
Herpes simplex virus type-2 (HSV2) infection increases HIV transmission.
We explore the impact of a potential prophylactic HSV2 vaccination on
HIV incidence in Africa using STDSIM an individual-based model. A
campaign that achieved 70\% coverage over 5 years with a vaccine that
reduced Susceptibility to HSV2 acquisition and HSV2 reactivation by 75\%
for 10 years, reduced HIV incidence by 30-40\% after 20 years (range
4-66\%). Over 20 years, in most scenarios fewer than 100 vaccinations
were required to avert one HIV infection. HSV2 vaccines could have a
substantial impact on HIV incidence. intensified efforts are needed to
develop an effective HSV2 vaccine. (C) 2008 Elsevier Ltd. All rights
reserved.
Tags
Women
Male circumcision
Human-immunodeficiency-virus
Herpes-simplex-virus
Sexually-transmitted
infections
Placebo-controlled trial
Genital herpes
Double-blind
Sex workers
Type-2